Contents

Non Allelic Homologous RecombinationEdit

Non allelic homologous recombination (NAHR) is a major mechanism by which the human genome acquires recurrent structural changes. Distinguished from allelic homologous recombination, NAHR occurs when recombination happens between similar DNA sequences that are not at the same chromosomal locus. These non-allelic homologous regions—most notably segmental duplications and low-copy repeats—create hotspots where misalignment during meiosis or mitosis can yield deletions and duplications of substantial size. The result is a spectrum of copy-number variation (CNV) that reshapes the genome across individuals and populations, sometimes with profound clinical consequences and other times with limited or no apparent effect.

In the broad view, NAHR ties together genome architecture, inheritance, and development. It operates most readily where highly similar sequences flank a region of interest. When crossing over occurs between these non-allelic repeats, one chromosome can lose the intervening segment while the homolog gains it. Depending on the orientation and location of the repeats, this process can also generate inversions or complex rearrangements. Because the same genomic architecture recurs across individuals, NAHR tends to produce recurrent, relatively predictable deletion or duplication events rather than solitary, unique anomalies. For this reason, clinicians and researchers often think in terms of recurrent microdeletion and microduplication syndromes that arise from NAHR at specific loci. Segmental duplications and Low-copy repeats are central to understanding these patterns, as are the DNA sequences like Alu repeats that populate the genome and can participate in mispairing events.

Mechanism and genomic substrates

NAHR relies on substantial sequence similarity between non-allelic regions. The most common substrates are Segmental duplications, genomic segments typically several kilobases to hundreds of kilobases long with high sequence identity. When two such regions align during chromosomal pairing, the conventional, precise exchange of genetic material can misalign, yielding unequal crossover events. The net effect is a gain of material on one chromosome and a loss on the other, yielding a duplication on one side and a corresponding deletion on the other. In some cases, NAHR can operate in a mitotic context, contributing to somatic mosaicism in cancers or other tissues.

High-throughput genomic technologies have revealed that NAHR is a leading cause of recurrent CNVs in humans. For example, recombination between flanking LCRs near certain loci consistently generates the same deletion or duplication across unrelated individuals. In clinical genetics, this predictability helps explain why groups of patients share characteristic symptom clusters even when their backgrounds differ. The field documents many instances where the same CNV arises repeatedly because the underlying NAHR-prone architecture is present in all humans. Low-copy repeats, Segmental duplication, and PMP22 are frequently cited in discussions of NAHR-prone regions, as are the mechanisms by which these CNVs influence gene dosage and expression.

Detection of NAHR-derived CNVs has evolved with technology. Early genetic testing focused on karyotyping; modern practice relies on array-based methods such as array comparative genomic hybridization and single-nucleotide polymorphism (SNP) arrays to identify copy-number changes. When a CNV is suspected to be NAHR-driven, targeted assays or whole-genome sequencing approaches may be used to map breakpoints and confirm the involvement of flanking repeats. Diagnostic contexts often pair genetic findings with clinical phenotypes to interpret the significance of the CNV for the patient’s health and development. MLPA is another common tool used to quantify copy number at candidate loci.

Recurrent CNVs and clinical associations

Because NAHR tends to generate deletions and duplications at the same genomic intervals, several well-characterized syndromes have become textbook examples of the mechanism. The following conditions illustrate how NAHR translates genomic architecture into clinical phenotypes:

  • 22q11.2 deletion syndrome: A recurrent microdeletion at the 22q11.2 region leads to a constellation of congenital heart defects, immune system anomalies, palatal abnormalities, and neurodevelopmental differences. The deletions are typically mediated by NAHR between flanking LCRs in the 22q11.2 locus. See 22q11.2 deletion syndrome for the clinical spectrum and genetic context.

  • Williams syndrome (7q11.23 deletion): Deletion of about 1.5–1.8 megabases at 7q11.23 produces distinctive facial features, cardiovascular issues, and a characteristic cognitive profile with relative strengths in language. This recurrent deletion is another classic NAHR-mediated event and is often discussed alongside the surrounding segmental architecture at 7q11.23. See Williams syndrome.

  • Smith-Magenis syndrome and Potocki-Lupski syndrome (17p11.2): The Smith-Magenis deletion involves the 17p11.2 region and yields intellectual disability, sleep disturbances, and dysmorphic features. The reciprocal PoKe counterpart, Potocki-Lupski syndrome, is caused by duplication of the same region. NAHR at 17p11.2 explains both conditions as sister events of unequal crossover between flanking segmental duplications. See Smith-Magenis syndrome and Potocki-Lupski syndrome.

  • Charcot-Marie-Tooth disease type 1A (CMT1A): This neuropathy is commonly caused by a duplication of the PMP22 gene on chromosome 17p12, facilitated by NAHR between flanking repeats. The corresponding deletion of PMP22 can produce a different neuropathic phenotype (HNPP) when the dosage is reduced. See Charcot-Marie-Tooth disease type 1A and PMP22.

  • 16p11.2 deletion and duplication: Individuals with a deletion or duplication at 16p11.2 display a range of neurodevelopmental and metabolic features, including associations with autism spectrum disorder and body mass index variation. NAHR at this locus is a prominent driver of these recurrent CNVs. See 16p11.2 deletion syndrome and 16p11.2 duplication syndrome.

  • 1q21.1 and 15q13.3 CNVs: Recurrent deletions and duplications at these loci are linked to neurodevelopmental differences and psychiatric phenotypes. As with other NAHR-driven CNVs, their recurrence reflects underlying genomic architecture rather than random events. See 1q21.1 deletion syndrome and 15q13.3 deletion/15q13.3 duplication.

These conditions illustrate how NAHR shapes the human genome in ways that are clinically meaningful. They also demonstrate why some genomic regions are described as hotspots for structural variation, and why clinicians must integrate molecular findings with individual patient presentations to determine prognosis and management.

Clinical implications and interpretation

NAHR-derived CNVs pose challenges and opportunities for medical genetics. On one hand, the recurrent nature of these events enables relatively straightforward genetic testing and counseling for families with a known locus. On the other hand, clinical interpretation can be complex when CNVs display variable expressivity and incomplete penetrance. Some individuals with a given NAHR-associated deletion or duplication may exhibit mild or no symptoms, while others show significant developmental or physiological effects. This variability underscores the importance of genotype–phenotype correlation, family studies, and careful consideration of additional genetic and environmental factors when diagnosing and advising patients. In prenatal settings, the detection of NAHR-related CNVs raises ethical and practical questions about risk assessment and decision-making, prompting ongoing discussion about screening criteria and communication. See Genetic counseling and Prenatal diagnosis for related topics.

The genetic community continues to refine our understanding of how NAHR interacts with other mechanisms of genome variation, such as non-homologous end joining and replication-based rearrangements, to produce an even wider array of structural changes. Advances in sequencing technologies, including Next-generation sequencing and high-resolution readouts, are helping to map breakpoints with increasing precision, enabling better predictions of phenotype and potential therapeutic avenues. See Genome sequencing for broader context on how these methods inform structural variation.

Evolutionary and population perspectives

NAHR is not merely a source of disease; it also reflects fundamental aspects of genome evolution. The presence of extensive Segmental duplication content in the human genome is a legacy of ancestral duplication events that created both raw material for gene innovation and a susceptibility to recurrent rearrangements. In evolutionary terms, CNVs generated by NAHR can alter gene dosage and contribute to adaptations or constraints in populations, while maintaining a trade-off between genomic flexibility and stability. Comparative studies with other species help illuminate how the architecture that predisposes NAHR in humans arose and persists, offering insight into why some lineages exhibit different propensities for CNV formation.

See also